Prognostic value of iodine-123 metaiodobenzylguanidine imaging in patients with heart failure

Experimental and Clinical Cardiology

Volumn 8, Issue 2, 2003, Pages 95-98

  Matsuo, Shinro ^a   Nakamura, Yasuyuki ^a   Matsumoto, Tetsuya ^a   Nakae, Ichiro ^a   Murata, Kiyoshi ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

B type natriuretic peptide; Congestive heart failure; Heart to mediastinum count ratio; Metaiodobenzylguanidine; Washout rates

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NORADRENALIN;

ADRENERGIC NERVE; ADULT; AGED; ARTICLE; CALCULATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MORBIDITY; MORTALITY; NERVE FUNCTION; NORADRENALIN BLOOD LEVEL; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS;

EID: 0346895167     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kawai C, Yui Y, Hoshino T, Sasayama S, Matsumori A. Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: A biopsy study. J Am Coll Cardiol 1983;2:834-40.
2. Sisson JC, Shapiro B , Meyers S, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28:1625-36.
3. Taki J, Nakajima K, Bunko H, Simizu M, Muramori A, Hisada K. Whole-body distribution of iodine 123 metaiodobenzylguanidine in hypertrophic cardiomyopathy: Significance of its washout from the heart. Eur J Nucl Med 1990;17:264-8.
4. Matsuo S, Takahashi M, Nakamura Y, Kinoshita M. Evaluation of cardiac sympathetic innervation with iodine-123-metaiodobenzyl-guanidine imaging in patients with silent myocardial ischemia. J Nucl Med 1996;37:712-7.
5. Nakajima K, Bunko H, Taki J, Shimizu M, Muramori A, Hisada K. Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J 1990;119:1329-37.
6. Shimizu M, Ino H, Okeie K, et al. Cardiac sympathetic activity in the asymmetrically hypertrophied septum in patients with hypertension or hypertrophic cardiomyopathy. Clin Cardiol 2000;23:365-70.
7. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
8. Matsuo S, Nakamura Y, Knoshita M, Horie M. Plasma B-type natriuretic peptide measurement in asymptomatic population. Int Med J 2003;10:105-8.
9. Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M. Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol 2002;9:407-12.
10. Maron BJ, Gottdienner JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A wide angle, two demensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:418-28.
11. Matsuo S, Nakamura Y, Takahashi M, Mistunami K, Kinoshita M. Myocardial metabolic abnormalities in hypertrophic cardiomyopathy assessed by iodine-123-labeled beta-methyl-branched fatty acid myocardial scintigraphy and its relation to exercise-induced ischemia. Jpn Circ J 1998;62:167-72.
12. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendation regarding quantitation in M-mode echocardiography: Results of survey of echocardiographic measurements. Circulation 1978;44:1072-83.
13. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Automic validation in the method. Circulation 1977;55:613-8.
14. Glowniak J, Kilty J, Amara S, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 1993;34:1140-6.
15. Takatsu H, Uno Y, Fujiwara H. Modulation of left ventricular iodine-125-MIBG accumulation in cardiomyopathic syrian hamsters using the renin-angiotensin system. J Nucl Med 1995;36:1055-61.
16. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;93:1667-76.
17. Matsuo S, Nakamura Y, Takahashi M, et al. Cardiac sympathetic dysfunction in athlete's heart detected by 123I MIBG scintigraphy. Jpn Circ J 2001;65:371-4.
18. Matsuo S, Nakamura Y, Matsui T, Matsumoto T, Kinoshita M. Detection of denervated but viable myocardium in cardiac sarcoidosis with I-123 MIBG and T1-201 SPECT imaging. Ann Nucl Med 2001;15:373-5.
19. Matsuo S, Nakamura Y, Kinoshita M. Post-stress left ventricular function in patients with coronary artery disease using thallium-201 ECG-gated single-photon emission tomography. Exp Clin Cardiol 2002;7:30-4.
20. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
21. Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: A prospective study. J Am Coll Cardiol 2003;41:231-8.